MEK inhibition increases lapatinib sensitivity via modulation of FOXM1

Current Medicinal Chemistry

Volumn 20, Issue 19, 2013, Pages 2486-2499

  Gayle, S S ^c   Castellino, R C ^b,c   Buss, M C ^b   Nahta, R ^a,b,c  

^a Departments of Pharmacology   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Breast cancer; ErbB2; HER2; Lapatinib; MEK; Resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; SELUMETINIB; TRASTUZUMAB; TRYPAN BLUE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; FOXM1 PROTO ONCOGENE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHARMACOGENETICS; PROTO ONCOGENE; TREATMENT RESPONSE; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84877987888     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320190008     Document Type: Article

References (34)

1. Bublil, E. M.; Yarden, Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr. Opin. Cell Biol., 2007, 19, 124-134. (Pubitemid 46386405)
2. Citri, A.; Yarden, Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Bio., 2006, 7, 505-516. (Pubitemid 44036456)
3. Yarden, Y.; Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Bio., 2001, 2, 127-137. (Pubitemid 33674041)
4. Eccles, S. A. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J. Mammary Gland Biol. Neoplasia, 2001, 6, 393-406.
5. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987, 235, 177-182. (Pubitemid 17231334)
6. Blackwell, K. L.; Burstein, H. J.; Storniolo, A. M.; Rugo, H.; Sledge, G.; Koehler, M.; Ellis, C.; Casey, M.; Vukelja, S.; Bischoff, J.; Baselga, J.; O'Shaughnessy, J. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol., 2010, 28, 1124-1130.
7. Eichhorn, P. J.; Gili, M.; Scaltriti, M.; Serra, V.; Guzman, M.; Nijkamp, W.; Beijersbergen, R. L.; Valero, V.; Seoane, J.; Bernards, R.; Baselga, J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res., 2008, 68, 9221-9230.
8. Brunner-Kubath, C.; Shabbir, W.; Saferding, V.; Wagner, R.; Singer, C. F.; Valent, P.; Berger, W.; Marian, B.; Zielinski, C. C.; Grusch, M.; Grunt, T. W. The PI3 kinase/mTOR blocker NVPBEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res. Treat., 2011, 129, 387-400.
9. Gayle, S. S.; Arnold, S. L.; O'Regan, R. M.; Nahta, R. Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance. Anticancer Agents Med. Chem., 2012, 12, 151-162.
10. O'Brien, N. A.; Browne, B. C.; Chow, L.; Wang, Y.; Ginther, C.; Arboleda, J.; Duffy, M. J.; Crown, J.; O'Donovan, N.; Slamon, D. J. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol. Cancer Ther., 2010, 9, 1489-1502.
11. Tanizaki, J.; Okamoto, I.; Fumita, S.; Okamoto, W.; Nishio, K.; Nakagawa, K. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Oncogene, 2011, 30, 4097-4106.
12. Zoppoli, G.; Moran, E.; Soncini, D.; Cea, M.; Garuti, A.; Rocco, I.; Cirmena, G.; Grillo, V.; Bagnasco, L.; Icardi, G.; Ansaldi, F.; Parodi, S.; Patrone, F.; Ballestrero, A.; Nencioni, A. Ras-induced resistance to lapatinib is overcome by MEK inhibition. Curr. Cancer Drug, 2010, 10, 168-175.
13. Bektas, N.; Haaf, A.; Veeck, J.; Wild, P. J.; Luscher-Firzlaff, J.; Hartmann, A.; Knuchel, R.; Dahl, E. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer, 2008, 8, 42.
14. Lam, E. W.; Francis, R. E.; Petkovic, M. FOXO transcription factors: key regulators of cell fate. Biochem. Soc. Trans., 2006, 34, 722-726. (Pubitemid 44796405)
15. Huang, H.; Tindall, D. J. Dynamic FoxO transcription factors. J. Cell Sci., 2007, 120, 2479-2487. (Pubitemid 47323857)
16. Wang, Z.; Ahmad, A.; Li, Y.; Banerjee, S.; Kong, D.; Sarkar, F. H. Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat. Rev., 2010, 36, 151-156.
17. Griner, S. E.; Joshi, J. P.; Nahta, R. Growth Differentiation Factor 15 Stimulates Rapamycin-Sensitive Ovarian Cancer Cell Growth and Invasion. Biochem. Pharmacol., 2012.
18. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 1984, 22, 27-55.
19. Liu, D.; Xing, M. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid, 2008, 18, 853-864.
20. Bekaii-Saab, T.; Phelps, M. A.; Li, X.; Saji, M.; Goff, L.; Kauh, J. S.; O'Neil, B. H.; Balsom, S.; Balint, C.; Liersemann, R.; Vasko, V. V.; Bloomston, M.; Marsh, W.; Doyle, L. A.; Ellison, G.; Grever, M.; Ringel, M. D.; Villalona-Calero, M. A. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J. Clin. Oncol., 2011, 29, 2357-2363.
21. O'Neil, B. H.; Goff, L. W.; Kauh, J. S.; Strosberg, J. R.; Bekaii-Saab, T. S.; Lee, R. M.; Kazi, A.; Moore, D. T.; Learoyd, M.; Lush, R. M.; Sebti, S. M.; Sullivan, D. M. Phase II study of the mitogenactivated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol., 2011, 29, 2350-2356.
22. Bhat, U. G.; Halasi, M.; Gartel, A. L. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS One, 2009, 4, e5592.
23. Kwok, J. M.; Myatt, S. S.; Marson, C. M.; Coombes, R. C.; Constantinidou, D.; Lam, E. W. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol. Cancer Ther., 2008, 7, 2022-2032.
24. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich, A.; et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 1989, 244, 707-712. (Pubitemid 19147683)
25. Blackwell, K. L.; Pegram, M. D.; Tan-Chiu, E.; Schwartzberg, L. S.; Arbushites, M. C.; Maltzman, J. D.; Forster, J. K.; Rubin, S. D.; Stein, S. H.; Burstein, H. J. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first-or second-line trastuzumab-containing regimens. Ann. Oncol., 2009, 20, 1026-1031.
26. Toi, M.; Iwata, H.; Fujiwara, Y.; Ito, Y.; Nakamura, S.; Tokuda, Y.; Taguchi, T.; Rai, Y.; Aogi, K.; Arai, T.; Watanabe, J.; Wakamatsu, T.; Katsura, K.; Ellis, C. E.; Gagnon, R. C.; Allen, K. E.; Sasaki, Y.; Takashima, S. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br. J. Cancer, 2009, 101, 1676-1682.
27. Fu, Z.; Malureanu, L.; Huang, J.; Wang, W.; Li, H.; van Deursen, J. M.; Tindall, D. J.; Chen, J. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat. Cell. Biol., 2008, 10, 1076-1082.
28. Kalin, T. V.; Wang, I. C.; Ackerson, T. J.; Major, M. L.; Detrisac, C. J.; Kalinichenko, V. V.; Lyubimov, A.; Costa, R. H. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res., 2006, 66, 1712-1720. (Pubitemid 43259956)
29. Kim, I. M.; Ackerson, T.; Ramakrishna, S.; Tretiakova, M.; Wang, I. C.; Kalin, T. V.; Major, M. L.; Gusarova, G. A.; Yoder, H. M.; Costa, R. H.; Kalinichenko, V. V. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res., 2006, 66, 2153-2161.
30. Hui, M. K.; Chan, K. W.; Luk, J. M.; Lee, N. P.; Chung, Y.; Cheung, L. C.; Srivastava, G.; Tsao, S. W.; Tang, J. C.; Law, S. Cytoplasmic Forkhead box M1 (FoxM1) in esophageal squamous cell carcinoma significantly correlates with pathological disease stage. World J. Surg., 2012, 36, 90-97.
31. Francis, R. E.; Myatt, S. S.; Krol, J.; Hartman, J.; Peck, B.; McGovern, U. B.; Wang, J.; Guest, S. K.; Filipovic, A.; Gojis, O.; Palmieri, C.; Peston, D.; Shousha, S.; Yu, Q.; Sicinski, P.; Coombes, R. C.; Lam, E. W. FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int. J. Oncol., 2009, 35, 57-68.
32. Zhao, F.; Lam, E. W. Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance. Front Med., 2012, 6, 376-380.
33. Chan, D.; Ngan, H. Abstract 2159: Targeting GRB7/ERK/FOXM1 signaling cascade is a promising therapeutic approach in ovarian cancer. Cancer Res., 2012, 72.
34. Leung, T. W.; Lin, S. S.; Tsang, A. C.; Tong, C. S.; Ching, J. C.; Leung, W. Y.; Gimlich, R.; Wong, G. G.; Yao, K. M. Overexpression of FoxM1 stimulates cyclin B1 expression. FEBS Lett., 2001, 507, 59-66. (Pubitemid 33000299)